<h3>Background</h3> Identification of biomarkers that can be used for the prognostic evaluation of NSCLC patients is important. The aim of this study was to evaluate the potential prognostic value of <i>XRCC1</i>, <i>ERCC1</i>, <i>ERCC2</i>, and <i>TP53</i> SNPs in completely resected NSCLC patients. <h3>Methods</h3> One hundred and thirty patients, who had been surgically treated for NSCLC between 2000 and 2012, were included in this study. Analysis of SNPs from peripheral blood cells was performed by PCR. <i>XRCC1</i> Arg399Gln, <i>ERCC1</i> Asn118Asn, <i>ERCC2</i> Lys751Gln, and<i>TP53</i> Arg72Pro polymorphisms were evaluated in conjunction with clinical and pathological parameters and survival. Kaplan–Meier method and Cox regression analysis were used. <h3>Findings</h3> In the univariate analysis for disease-free survival (DFS), postoperative stage (hazard ratio [HR] 0.50, 95% confidence interval [CI] 0.26–0.96; <i>p</i>=0.03), <i>ERCC2</i> genotype (HR 2.47, 95% CI 1.28–4.78; <i>p</i>=0.007), and PET-CT staging (HR 0.27, 95%CI 0.14–0.52; <i>p</i><0.001) were significant parameters. Adjuvant chemotherapy, age, and the other SNPs were not significant. In the multivariate analysis, post-operative stage (HR 0.40, 95% CI 0.20–0.81; <i>p</i>=0.01), <i>ERCC2</i> genotype (HR 2.66, 95% CI 1.35–5.27; <i>p</i>=0.005), PET-CT staging (HR 0.24, 95% CI 0.12–0.47; <i>p</i><0.001) retained their significance. Median DFS was 56.5months (95% CI 24.6–88.4) for the <i>ERCC2</i> mutant (TT) and heterozygote (GT) genotypes, and 28.3months (95% CI 20.8–35.8) for the <i>ERCC2</i> normal (GG) genotype (p =0.005). <h3>Interpretation</h3> In addition to stage and PET-CT staging, <i>ERCC2</i> genotype independently predicted DFS in resected NSCLC patients. Future prospective studies are needed for the further evaluation of potential prognostic SNPs in resected NSCLC.